KREJČÍ, Pavel, Shunichi MURAKAMI, Jiřina PROCHÁZKOVÁ, Lukáš TRANTÍREK, Katarína CHLEBOVÁ, Zhufeng OUYANG, Anie AKLIAN, Jiří SMUTNÝ, Vítězslav BRYJA, Alois KOZUBÍK and Wiliam R. WILCOX. Nf449 is a novel inhibitor of fibroblast growth factor receptor 3 (fgfr3) signaling active in chondrocytes and multiple myeloma cells. J. Biol. Chem. 2010, vol. 285, No 27, p. 20644-20653. ISSN 0021-9258. Available from: https://dx.doi.org/10.1074/jbc.M109.083626.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Nf449 is a novel inhibitor of fibroblast growth factor receptor 3 (fgfr3) signaling active in chondrocytes and multiple myeloma cells
Authors KREJČÍ, Pavel (203 Czech Republic, guarantor, belonging to the institution), Shunichi MURAKAMI (840 United States of America), Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution), Lukáš TRANTÍREK (203 Czech Republic), Katarína CHLEBOVÁ (703 Slovakia, belonging to the institution), Zhufeng OUYANG (840 United States of America), Anie AKLIAN (840 United States of America), Jiří SMUTNÝ (203 Czech Republic, belonging to the institution), Vítězslav BRYJA (203 Czech Republic, belonging to the institution), Alois KOZUBÍK (203 Czech Republic, belonging to the institution) and Wiliam R. WILCOX (840 United States of America).
Edition J. Biol. Chem. 2010, 0021-9258.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30105 Physiology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 5.328
RIV identification code RIV/00216224:14310/10:00074547
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1074/jbc.M109.083626
UT WoS 000279228600028
Keywords in English ERK MAP KINASE; ACTIVATING MUTATIONS; PROLIFERATION; SURAMIN; PATHWAY; DIFFERENTIATION; ACHONDROPLASIA; ASSOCIATION; ANTAGONIST; EXPRESSION
Tags AKR, rivok
Changed by Changed by: Ing. Andrea Mikešková, učo 137293. Changed: 11/4/2015 17:37.
Abstract
The FGFR3 receptor tyrosine kinase represents an attractive target for therapy due to its role in several human disorders, including skeletal dysplasias, multiple myeloma, and cervical and bladder carcinomas. By using molecular library screening, we identified a compound named NF449 with inhibitory activity toward FGFR3 signaling. In cultured chondrocytes and murine limb organ culture, NF449 rescued FGFR3-mediated extracellular matrix loss and growth inhibition, which represent two major cellular phenotypes of aberrant FGFR3 signaling in cartilage. Similarly, NF449 antagonized FGFR3 action in the multiple myeloma cell lines OPM2 and KMS11. In cell-free kinase assays, NF449 inhibited the kinase activity of both wild type and a disease-associated FGFR3 mutant (K650E) in a fashion that appeared non-competitive with ATP.
Links
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
PrintDisplayed: 26/8/2024 23:28